Revvity Beats Q4 Estimates, Offers Cautious Optimism Amid Long-Term Growth Challenges
Life sciences firm Revvity (NYSE:RVTY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, though analysts remain watchful of the company's ability to sustain momentum beyond recent quarters.